Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of “Buy” by Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have earned a consensus rating of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $92.17.

A number of research analysts recently weighed in on the stock. Oppenheimer initiated coverage on shares of Keros Therapeutics in a research note on Tuesday, June 25th. They set an “outperform” rating and a $102.00 target price on the stock. Truist Financial restated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research note on Tuesday, June 18th.

Keros Therapeutics Stock Up 4.0 %

KROS stock opened at $52.32 on Friday. The business’s 50-day moving average price is $47.35 and its 200-day moving average price is $55.41. The stock has a market cap of $1.89 billion, a P/E ratio of -10.16 and a beta of 1.23. Keros Therapeutics has a twelve month low of $27.02 and a twelve month high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share for the quarter, beating the consensus estimate of ($1.33) by $0.12. The firm had revenue of $0.08 million for the quarter. Keros Therapeutics’s quarterly revenue was down 97.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.26) earnings per share. On average, equities research analysts expect that Keros Therapeutics will post -4.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. ADAR1 Capital Management LLC bought a new position in Keros Therapeutics during the fourth quarter valued at approximately $27,367,000. Redmile Group LLC bought a new position in shares of Keros Therapeutics during the 1st quarter valued at approximately $36,576,000. Darwin Global Management Ltd. grew its holdings in shares of Keros Therapeutics by 35.4% in the first quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock valued at $95,060,000 after purchasing an additional 375,523 shares in the last quarter. Franklin Resources Inc. increased its position in Keros Therapeutics by 47.9% in the fourth quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock worth $27,809,000 after purchasing an additional 226,674 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Keros Therapeutics by 18.8% in the third quarter. Vanguard Group Inc. now owns 1,406,431 shares of the company’s stock worth $44,837,000 after purchasing an additional 222,652 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.